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INTRODUCTION
The majority of lung cancer cases, about
90%, can be attributed to cigarette smoking,1
but no more than 20% of smokers develop
lung cancer.2 The prevalence of tobacco usage
is on the increase in developing countries.3
Other factors, such as diet, chronic lung
diseases, occupational and possibly envi-
ronmental agents have been shown to con-
tribute to the development of this cancer.4
Genetic factors seem to play a role in the
causality of lung cancer, but the precise
characteristics influencing lung cancer
susceptibility are not known. Such genetic
factors are easily obscured by the strong
environmental determinants of lung cancer,
particularly smoking.4
Various studies have shown elevations in
the risks for different cancers among those who
reported cancer in relatives.5-10 Evidence of
some degree of familial aggregation of lung
cancer is brought out in most familial studies.
Since the pioneering study of Tokuhata and
Lilienfeld11 on familial aggregation of lung
cancer, some studies have consistently
demonstrated an increased prevalence of
cancer among relatives of lung cancer patients,
with risks varying from 1.3 to 12.2.12-22
However, other studies concluded that there
was little evidence of familial cancer clusters
related to lung cancer risk.23,24 Some authors
have suggested that a genetic predisposition
to lung cancer may contribute to familial
aggregation of this cancer.2,20,22,25 In addition,
studies of familial cancer aggregation may
provide important insights into the under-
standing of the interplay between envi-
ronmental and genetic risk factors in cancer
development.
Lung cancer is the most common neoplastic
disease among Brazilian males and the main
cause of death from cancer. Since the 1970s the
incidence and mortality rate of lung cancer have
been rising, and during the 1990s have been
increasing among females.26 This pattern has
been associated with an increase in the prevalence
of tobacco smoking.27,28 No studies have been
published on familial cancer aggregation and
lung cancer in Brazil. However the results of a
case-control study conducted in Rio de Janeiro
showed that polymorphism of the Cyp1A1 gene,
encoding for an enzyme involved in the
metabolism of tobacco carcinogens, was
associated with lung cancer risk.29
The objective of this study was to examine
the effect that reported histories of cancer
among first-degree relatives had on lung cancer
among the participants in a case-control study
carried out in the metropolitan region of São
Paulo (MRSP), an area with high incidence
and mortality rates of lung cancer.
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METHODS
A hospital-based case-control study was
structured so as to detect incident cases of
primary lung cancer among males and females
in 14 hospitals where the majority of lung
cancer cases in the MRSP are admitted. In-
formation was gathered on cancer in first-de-
gree relatives (parents, siblings and offspring),
tobacco smoking, passive smoking in
childhood and adult life, socioeconomic
status, occupational exposures and medical
history. Some additional details on the
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CONTEXT: Around 90% of lung cancer worldwide is
attributable to cigarette smoking, although less than
20% of cigarette smokers develop lung cancer. Other
factors such as diet, chronic lung diseases, occupation
and possibly environmental agents also contribute to
this cancer. Genetic factors seem to play a role in lung
cancer, but the precise characteristics influencing lung
cancer susceptibility are not known, since genetic
factors are easily obscured by the strong environmental
determinants of lung cancer, particularly smoking.
OBJECTIVE: To estimate the effect that cancer
occurrence among first-degree relatives has on the
risk of lung cancer.
DESIGN: Hospital-based case-control study.
SETTING: The metropolitan region of São Paulo, Brazil.
PARTICIPANTS: 334 incident lung cancer cases and
578 controls matched by hospitals.
MAIN MEASUREMENTS: By means of a structured
questionnaire, cases and controls were interviewed
about cancer occurrence in first-degree relatives,
tobacco smoking, exposure to passive smoking,
occupation, migration and socioeconomic status.
Non-conditional logistic regression was used to
calculate the risk of familial cancer aggregation, the
effect of cancer in first-degree relatives and smoking
in conjunction, and for controlling confounders.
RESULTS: The adjusted odds ratio (OR) revealed a slight,
but not statistically significant, excess risk of lung
cancer for subjects with a history of lung cancer in
relatives (OR 1.21; 95% confidence interval [CI]
0.50 – 2.92). The same was found among those
with a history of other tobacco-related cancers in
relatives (OR 1.36; 95% CI 0.87 – 2.14). A step
gradient effect was observed regarding lung cancer
risk, in accordance with increases in the number
of pack-years of cigarette consumption. An
interaction between familial cancer aggregation
and tobacco smoking was detected.
CONCLUSIONS: A mildly elevated risk of lung cancer
among persons with a positive history of lung and
other tobacco-related cancers was observed. The
finding of an interaction between the variables of
familial cancer aggregation and smoking suggests
that familial cancer aggregation could be
considered as a marker of susceptibility,  increasing
the risk of lung cancer among smokers. These results
improve our knowledge of lung carcinogenesis and
can guide future cancer genetic studies.
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structure of the study and analysis of
occupational risk factors have already been
described in a previous publication.30
A total of 912 persons were included in
the analysis, of whom 334 were cases and 578
controls. The cases chosen for the study were
newly diagnosed as having lung cancer,
according to the International Classification
of Disease, ninth revision (ICD-9),31 rubric
162, between January 1989 and June 1991.
The diagnosis was assessed from hospital
records and only cases confirmed by histology
or cytology were accepted. Cases confirmed
by cytology were assumed to be of undiffe-
rentiated histological type. Eligible cases with
a definite diagnosis other than lung cancer
were reclassified as controls whenever the
diagnosis was among those retained as
admissible for controls. Only patients who had
been resident for at least six months in the
MRSP were included, and all patients were
interviewed in person. Controls were enrolled
from the same hospitals and during the same
period as the cases, and also had to have been
resident in the MRSP for at least six months.
To determine the controls’ eligibility, their
diagnoses abstracted from medical records
were coded according to the ICD-9. Patients
with chronic obstructive respiratory diseases,
circulatory diseases and smoking-related
cancers (bladder, larynx, esophagus, oral
cavity, pharynx, pancreas, kidney and renal
pelvis) were excluded.
A standard questionnaire specifically
drawn up for the gathering of information on
the study variables (family cancer history,
tobacco smoking, passive smoking, occu-
pation, migration and socioeconomic status)
was applied to both cases and controls. Family
cancer history was recorded regarding any first-
degree relative (mother, father, sibling, son or
daughter) having a cancer at any anatomical
site. By means of a structured interview, the
health status of each first-degree relative,
including the disease diagnosis of sick relatives
and the cause of death of deceased relatives
were recorded. Pathological confirmation of
cancer, and smoking habits of relatives were
not obtained.
Odds ratio (OR) and 95% confidence
intervals (CI) were calculated as approximations
of relative risk.32 The risk of lung cancer was
estimated by comparing subjects reporting a
positive history of cancer in first-degree relatives
with those who did not. Cases and controls were
stratified according to the number of cancer
cases in first-degree relatives and the proportion
of reported cases over the total number of
studies in Brazil33 and worldwide.4 The main
diagnoses for controls were: infectious and
parasitic diseases (23.5%), non-tobacco related
neoplasms (17.5%), diseases of the digestive
system (15.1%), endocrine, nutritional,
metabolic diseases and immune disorders
(7.4%). The remaining controls had diverse
diseases such as bone fracture, rheumatoid
arthritis, skin diseases, and in women,
childbirth complications. Males had a higher
proportion of infectious diseases and a lower
proportion of neoplasms than did females.
From a combination of per capita income
and level of education, four socioeconomic
tiers were established. Males in the highest
socioeconomic level showed a slightly higher
but non-significant risk of developing lung
cancer than did those in the lowest tier (OR
1.34; 95% CI 0.79 – 2.29), with this
difference being more pronounced among
females (OR 3.75; 95% CI 1.36 – 10.29).
The prevalence of any cancer in first-degree
relatives among cases (27.2%) was higher than
among controls (21.3%), but no statistically
significant association was found (OR 1.16;
95% CI 0.82 – 1.65). Nor was any correlation
found between the risk of lung cancer and
number of cancers among first-degree relatives
(Table 2). A slight excess risk was found within
the smokers group (OR 1.24; 95% CI 0.81 –
relatives. The risk of lung cancer was also
estimated for different groups of neoplasm
among relatives: lung cancer, tobacco-related
cancers other than lung cancer, and other
cancers not related to tobacco. The analysis of
tobacco smoking was based on categories of
cumulative consumption expressed in pack-
years. The OR and the 95% CI estimates were
obtained by non-conditional logistic regression
using the maximum likelihood estimate,
adjusting for sex, age, smoking and socioecono-
mic status. Socioeconomic status was classified
into four levels based on a combination of
income and level of education.
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RESULTS
Selected characteristics of cases and controls
are shown in Table 1. Of the 334 lung cancer
cases 76.6% were men and among the 578
hospital controls 64.2% were men. The age
range of cases was 36-90 years, and for controls
33-90 years. In males, squamous cell carcinoma
was the most frequent histological type and in
females, adenocarcinoma was predominant.
Only 28 lung cancer cases (8.4%) did not have
diagnoses established by histology. The
distribution of lung cancer cases according to
age, gender and histological type of tumor was
similar to what has been reported in previous
Table 1. Selected characteristics of cases and controls by sex
CHARACTERISTIC MALES FEMALES
Cases Controls Cases Controls
(n = 207) (n = 371) (n = 78) (n = 256)
n (%) n (%) n (%) n (%)
AGE1
< 50 years 25 (9.8) 75 (20.2) 11 (14.1) 31 (15.0)
50-59 years 77 (30.1) 119 (32.1) 27 (34.6) 54 (26.1)
60-69 years 95 (37.1) 112 (30.2) 29 (37.2) 82 (39.6)
≥ 70 years 59 (23.0) 65 (17.5) 11 (14.1) 40 (19.3)
HISTOLOGICAL TUMOR TYPE
Squamous cell carcinoma 120 (46.9) - 22 (28.2) -
Adenocarcinoma 59 (23.0) - 29 (37.2) -
Small cell carcinoma 36 (14.1) - 12 (15.4) -
Large cell carcinoma 11 (4.3) - 2 (2.5) -
Other, mixed and undifferentiated2 30 (11.7) - 13 (16.7) -
DIAGNOSES OF CONTROLS
(ICD-9 codes3)
Infectious and parasitic diseases
(001 - 139) - 111 (29.9) - 25 (12.1)
Non-tobacco related neoplasms
(140 - 239) - 43 (11.6) - 58 (28.0)
Endocrine, nutritional and metabolic
diseases and immune disorders
(240 – 279) - 20 (5.4) - 23 (11.1)
Diseases of the digestive system
(520 - 579) - 50 (13.5) - 37 (17.9)
Other diagnoses - 147 (39.6) - 64 (30.9)
1 Age range: 36-90 for cases; 33-90 for controls.
2 Including all tumors confirmed by cytology.
3ICD-9 = International Classification of Diseases, Ninth Edition.31
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1.90), and for nonsmokers (OR 1.53; 95% CI
0.61 – 3.83), among those for whom 10% or
more of their first-degree relatives had a positive
history of cancer (Table 3). The risk of lung
cancer according to type of cancer, as reported
by category of relatives, did not reveal any
significant odds ratio (Table 4). As Table 5
demonstrates, there were elevated risks among
subjects whose relatives had lung cancer (OR
1.73; 95% CI 0.75 – 3.96) and other tobacco-
related cancers (OR 1.67; 95% CI 1.11 – 2.53).
However, controlling for smoking dramatically
affected the risk for those reporting lung cancer
among relatives (OR 1.21; 95% CI 0.50 –
2.92), or other tobacco-related cancers (OR
1.36; 95% CI 0.87 – 2.14).
Tobacco smoking was an important risk
factor for lung cancer and a step gradient effect
was observed in relation to increasing numbers
of pack-years of cigarettes smoked, which was
stratified into five groups (Table 6). The
increase in the risk can be seen from the reports
of cancer in relatives for each cumulative
consumption pack-years stratum, except for
the 1-20 pack-year stratum.
Table 7 shows an analysis of smoking
according to two strata of cumulative
consumption (0-20 and 21 or more pack-
years), combined with the dichotomous
variable of cancer among relatives. No effect
of familial cancer aggregation was detected
when there was a consumption of less than
20 pack-years, which suggests an interaction
between smoking and familial cancer
aggregation. Further stratification by gender
or age made no difference to the detection of
this interaction (Table 8).
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DISCUSSION
The objective of this study was to examine
how familial cancer aggregation affects the risk
of lung cancer. Evidence for the genetic basis
of cancer has increased over recent decades and
thus an assessment of familial cancer aggre-
gation may play an important role in epide-
miological studies. Excessive frequency of a
trait or disorder within specific families as
compared with the population at large is the
focus of familial aggregation studies. Various
cancer studies have noted this relationship, but
the main problem arising from the results of
epidemiological studies lies in the difficulty
in balancing the influence of heredity versus
shared environmental factors.34 Inter-
individual variation in response to xenobiotics
and their potential carcinogenic effects could
be mediated by inherited genetic predis-
position, although familial aggregation may
also be explained by the fact that people of
the same family tend to share the same habits,
such as tobacco smoking, alcohol drinking,
diet and occupation. The ability to disentangle
the role of a genetic/familial component from
the effect of tobacco smoking on lung cancer
risk can improve our knowledge of lung
carcinogenesis and have an impact on cancer
prevention.
Several studies of familial aggregation of
lung cancer have suggested an underlying
genetic susceptibility.2,11-13,15-22 Sellers et al.14
provided strong evidence of Mendelian
inheritance in lung cancer, but the study by
Yang et al.35 rejected the Mendelian model as
an explanation of lung cancer occurrence.
The most recent publications of population-
based studies of familial aggregation of lung cancer
used the strategy of investigating only nonsmokers.
Table 2. Odds ratio for lung cancer according to the number of
cancer cases among first-degree relatives
Cancer in relatives1 Cases Controls
(n = 334) (n = 578) OR2 (95% CI)
None3 230 429 1.0
Any 91 123 1.16 (0.82 – 1.65)
1 case 73 95 1.26 (0.86 – 1.84)
2 cases 15 22 0.96 (0.47 – 1.99)
≥ 3 cases 3 6 0.60 (0.13 – 2.83)
1 Any cancer in parents and siblings; 2 Odds ratio adjusted for gender, age, socioeconomic status (four levels) and smoking (pack-years); 3 Reference category.
Table 3. Odds ratio for lung cancer according to the percentage of
first-degree relatives with cancer
Percentage of cancer Cases Controls
in relatives1 (n = 334) (n = 578) OR2 (95% CI)
TOTAL3
< 10% 23 31 1.15 (0.61 – 2.15)
≥ 10% 65 87 1.12 (0.75 – 1.67)
SMOKERS3
< 10% 22 19 1.37 (0.71 – 2.67)
≥ 10% 57 55 1.24 (0.81 – 1.90)
NONSMOKERS3
< 10% 1 12 0.44 (0.05 – 3.71)
≥ 10% 8 32 1.53 (0.61 – 3.83)
1 Any cancer in parents and siblings; 2 Odds ratio adjusted for gender, age, socioeconomic status (four levels); and smoking (pack-years) for the total
group; 3 Reference category: no cancer reported among relatives.
Table 4. Odds ratio for lung cancer according to the number of cancer cases
by category of first-degree relatives
Cancer in first-degree Cases Controls
relatives1 (n = 334) (n = 578) OR2 (95% CI)
None3 230 429 1.00
Mother
Any 27 43 1.10 (0.64 – 1.91)
Not tobacco-related 10 19 0.88 (0.38 – 2.04)
Tobacco-related4 14 19 1.37 (0.64 – 2.94)
Lung 3 5 1.01 (0.21 – 4.97)
Father
Any 28 43 1.09 (0.63 – 1.89)
Not tobacco-related 8 17 0.87 (0.34 – 2.19)
Tobacco-related4 16 19 1.48 (0.70 – 3.13)
Lung 4 7 0.68 (0.18 – 2.53)
Siblings
Any 52 61 1.20 (0.76 – 1.87)
Not tobacco-related 14 21 1.10 (0.52 – 2.35)
Tobacco-related4 31 33 1.29 (0.73 – 2.30)
Lung 7 7 1.05 (0.34 – 3.21)
1 No cancer was reported in the offspring; 2 Adjusted for gender, age, socioeconomic status (four levels), smoking (pack-years), and number of siblings
(group of siblings); 3 Reference category; 4 Bladder, larynx, esophagus, oral cavity, pharynx, pancreas, kidney and renal pelvis.
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The study by Schwartz et al.17 suggested the
hypothesis of genetic susceptibility to lung cancer,
since the familial aggregation was found only
among the relatives of younger nonsmoking lung
cancer cases and among younger relatives. Similar
results were found by Kreuzer et al.19 and Yang et
al.36 Wu et al.16 studied only female nonsmokers
and found no association between family history
of cancer and risk of lung cancer among
nonsmokers, but did suggest that the risk of lung
cancer increased among females with a female
relative (mother or sister) with lung cancer.
However, the lack of additional information about
lifestyle risk factors among the family members
restricted the interpretation of results of that study.
Brownson et al.18 investigated nonsmokers and
ex-smokers and, noting a slight increase in risk,
they suggested an interaction between genetic
susceptibility and smoking due to the increased
chances of lung and oral cavity cancer among
former smokers. Yang et al.35 studied nonsmoking
males and females, and suggested that the pattern
of lung cancer occurrence in families of non-
smoking lung cancer patients differs from that in
families of smoking lung cancer patients. This was
based on the fact that the mean age for the onset
of lung cancer among female relatives was 55 years
for smokers and 88 years for nonsmokers.
Such results are suggestive of the presence
of a high-risk gene contributing to early-onset
lung cancer in a population where the pro-
bands are nonsmokers. Nevertheless, these
results still do not clarify whether the evidence
supporting a familial association suggests that
the etiology of lung cancer includes shared
genes or shared environments, or both of
these. Certainly, environment factors such as
passive smoking must have some influence on
lung cancer occurrence in the family. However,
many other non-environmental mechanisms
might provide additional explanations. Such
mechanisms may include common genetic
polymorphism of carcinogen-metabolizing
enzymes, mutations of tumor suppressor genes
or variability in DNA repair activity.37
The results from this study have revealed
a slight, but non-statistically significant, excess
lung cancer risk among those who reported
tobacco-related cancer cases and lung cancer
among first-degree relatives after controlling
for the confounding effect of tobacco (Table
5). These results are contrary to those risks
found in the classical case-control studies on
the influence of familial cancer aggregation
factors on lung cancer.11,12 However, they are
in general compatible with the low excess risk
found by Shaw et al.,13 Wu et al.,16 Brownson
et al.18 and Gupta et al.21
The magnitude of the risk from familial
cancer aggregation was higher among non-
smokers than for smokers, but the odds ratios
were not statistically significant (Table 3).
However, when the influence of smoking on
subjects whose relatives had cancer was
examined, an interaction was detected (Table
6 and 7).
Kreuzer et al.19 detected remarkable
differences in lung cancer risk between
probands in younger age groups who reported
cancer in relatives or not, but not for older age
groups. This finding is also supported by the
work of Gauderman and Morrison.25 In our
study there was no difference in the interaction
of cigarette smoking with familial cancer
aggregation according to age group (< 60 and
60 years and over) or gender (Table 8).
The results of this study may have been
affected by bias. There may have been
interference in family history investigations
caused by misclassification. Geographical
separation limits the availability of
information on family histories of disease, thus
resulting in an underreporting of familial
cases.38 Moreover, positive histories may be
inaccurate because metastatic cancer sites can
often be mistaken for primary ones. In this
Table 5. Odds ratio for lung cancer according to the
type of cancer in first-degree relatives
Type of cancer in Cases Controls
relatives1 (n = 334) (n = 578) OR2 (95% CI)
OR adjusted for gender, age and socioeconomic status2
No cancer3 239 452 1.0
Not tobacco-related cancers 30 54 1.02 (0.63 – 1.66)
Tobacco-related4 53 60 1.67 (1.11 – 2.53)
Lung 12 12 1.73 (0.75 – 3.96)
OR adjusted for gender, age, socioeconomic status and smoking5
No cancer3 230 429 1.0
Not tobacco-related cancers 29 53 0.93 (0.55 – 1.57)
Tobacco-related3 50 58 1.36 (0.87 – 2.14)
Lung 12 12 1.21 (0.50 – 2.92)
1 Parents and siblings; 2 Considering four levels, from level 1 (lowest level) to level 4 (highest level), based on
a combination of income per capita and level of education; 3 Reference category;  4 Bladder, larynx, esophagus,
oral cavity, pharynx, pancreas, kidney and renal pelvis; 5 Pack-years.
Table 6. Joint effect on lung cancer risk of smoking (5 strata)
and cancer among first-degree relatives (2 strata)
Smoking Any cancer Cases Controls
(pack-years) in relatives1 (n = 334) (n = 578) OR2 (95% CI)
Nonsmoker No 28 162 1.00
Yes 9 47 1.08 (0.47 – 2.47)
1 – 20 No 39 88 3.36 (1.87 – 6.03)
Yes 6 24 1.86 (0.68 – 5.10)
21 – 40 No 50 85 5.18 (2.80 – 9.58)
Yes 17 19 7.17 (3.19 – 16.13)
41 – 60 No 55 49 8.93 (4.78 – 16.65)
Yes 29 18 11.73 (5.44 – 25.25)
≥ 61 No 58 45 10.03 (5.32 – 18.91)
Yes 30 15 14.90 (6.68 – 33.25)
1 Parents and siblings; 2 Adjusted for gender, age and socioeconomic status (four levels).
Table 7. Joint effect on lung cancer risk of smoking (2 strata) and
cancer among first-degree relatives (2 strata)
Smoking Cancer Cases Controls
(pack-years) in relatives1 (n = 334) (n = 578) OR2 (95% CI)
0 – 20 No3 67 250 1.00
Yes 15 71 0.79 (0.42 – 1.47)
≥ 21 No 163 179 3.53 (2.49 – 5.01)
Yes 76 52 5.29 (3.37 – 8.30)
1 Any cancer in parents and siblings; 2 Odds ratio adjusted for age and socioeconomic status (four levels); 3 Reference category.
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study, cancer diagnoses among relatives were
not histologically confirmed. Love et al.39
estimated the accuracy of family cancer history
reports and concluded that information on
primary-site cancer among first-degree
relatives was 83% accurate.
The lack of data on relatives’ ages may
also have distorted the estimates, considering
that subjects with older relatives would be
expected to have more cancer in the family
than would subjects with younger relatives.
In an effort to correct for this impediment,
we examined the risk by category of first-
degree relative. However, no difference in lung
cancer risk was noted from reports of cancer
occurrences among mothers, fathers or siblings
(Table 4).
Another major problem in this study was
the lack of data on smoking among first-degree
relatives. Cancer among relatives is likely to
be related to smoking exposure within the
family and thus, without this information, a
familial/genetic effect cannot be clearly
separated from the smoking effect. Table 5
shows how the control for smoking exposure
affected the OR of the association between
cancer among first-degree relatives and lung
cancer. This suggests that incorporating
information on relatives who smoke might
further reduce the observed association.
Use of hospital controls may have caused
selection bias, since 11.6% of male controls
and 28.0% of female controls were cancer
patients. If a positive familial history of cancer
was a risk factor for cancers at sites other than
the lung, then the choice of cancer controls
would have resulted in a bias towards nullity.
However, the exclusion of cancer controls did
not modify the results substantially.
Lack of statistical power may have been
another potential and additional limitation
to this study. The predominantly null results
presented in Tables 2 to 5 may be due to
this fact.
Despite these possible limitations, the
findings showing a mild effect of familial
aggregation cancers suggest that common
susceptibility genes may act to increase the risk
of lung cancer. Reinforcing this, the stratified
analysis suggested evidence of an interaction
between a positive history of neoplasm in the
family and tobacco smoking (Tables 6 and 7).
Two facts could possibly explain these
interaction findings: (a) residual confounding
in the category of 20 and more pack-years; or
(b) genetic or environmental familial factors
acting on some carcinogenic pathways relevant
only for heavy smokers, such as detoxification
or damage repair above a certain threshold.
Tobacco smoking, the main environ-
mental risk factor for lung cancer, is strictly
dependent on cultural and demographic cha-
racteristics. Recent studies have suggested that
the initiation of smoking and nicotine depen-
dence may be linked to genetic factors.40 There
is considerable variation in individuals’ sus-
ceptibility to lung cancer, and it has been
postulated that this is due to genetic poly-
morphisms of carcinogen metabolizing
enzymes.41 However, no clear mechanisms
have been established to explain this
relationship of interactions between genetic
polymorphisms and tobacco carcinogen
metabolism, and their further effects on lung
cancer. For example, glutathione S-transferase
(GST) null genotypes seem to be related to a
higher incidence of polycyclic aromatic
hydrocarbon DNA adducts and a higher risk
of lung cancer,42-45 yet some studies have found
no such associations.46 One study showed an
increased risk of lung cancer among
individuals combining GST null genotype and
a smoking consumption of at least 35 pack-
years.47 Certainly, many tobacco carcinogens
are metabolized by enzymes of the P450
cytochrome family and GST family. Poly-
morphisms of cytochrome P450, Cyp1A1 and
Cyp1A2, and the GST isoenzyme GSTM1
could have implications for polycyclic
aromatic hydrocarbon metabolism.48 This may
explain the increases in the probability of lung
cancer among smokers of more than 20 pack-
years, as found in this study.
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
CONCLUSION
This study reports results from a hospital-
based case-control study showing a mildly
elevated risk of lung cancer among persons
with a positive family history of lung and other
tobacco-related cancers. The results suggest
that familial cancer clusters may have some
connections with tobacco smoking. The
finding of an interaction between the variables
of familial cancer aggregation and cigarette
smoking on the risk of lung cancer may guide
future genetic studies and improve our
knowledge of lung cancer carcinogenesis.
Table 8. Joint effect on lung cancer risk of smoking (2 strata) and
cancer among first-degree relatives (2 strata), by gender and age
Smoking Cancer Cases Controls
(pack-years) in relatives1 (n = 334) (n = 578) OR2 (95% CI)
GENDER
Males 0 – 20 No3 29 120 1.00
Yes 4 29 0.50 (0.16 – 1.56)
≥ 21 No 148 163 3.84 (2.39 – 6.16)
Yes 66 45 5.50 (3.13 – 9.68)
Females 0 – 20 No3 38 130 1.00
Yes 11 42 0.93 (0.43 – 2.04)
≥ 21 No 15 16 3.25 (1.42 – 7.42)
Yes 10 7 4.89 (1.68 – 14.25)
AGE
< 60 years 0 – 20 No3 30 122 1.00
Yes 7 27 1.00 (0.39 – 2.56)
≥ 21 No 72 100 3.66 (2.07 – 6.46)
Yes 27 24 4.96 (2.45 – 10.07)
≥ 60 years 0 – 20 No3 37 128 1.00
Yes 8 44 0.62 (0.27 – 1.45)
≥ 21 No 91 79 3.86 (2.25 – 6.63)
Yes 49 28 5.74 (2.97 – 11.09)
1 Parents and siblings; 2 Odds ratio adjusted for age, gender and socioeconomic status (four levels); 3 Reference category.
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INTRODUÇÃO: Cerca de 90% dos casos de
câncer de pulmão no mundo são atribuíveis
ao tabagismo, porém menos de 20% dos
fumantes desenvolvem câncer de pulmão.
Fatores como dieta, doenças pulmonares
crônicas, ocupação e, possivelmente, expo-
sições ambientais também têm papel na
etiologia desse câncer. Os fatores genéticos
parecem influir na ocorrência da doença, mas
as características que influenciam a susce-
tibilidade à neoplasia pulmonar não são preci-
samente conhecidas, obscurecidas pela forte
influência dos fatores ambientais na deter-
minação da doença, particularmente o taba-
gismo.
OBJETIVOS: Estimar o efeito da ocorrência de
câncer em parentes de primeiro grau no risco
de câncer de pulmão.
TIPO DE ESTUDO: Estudo caso-controle de
base hospitalar.
LOCAL: Região Metropolitana de São Paulo.
PARTICIPANTES: 334 casos de neoplasia
pulmonar e 578 controles emparelhados por
hospital.
VARIÁVEIS ESTUDADAS: Casos e controles
foram entrevistados com respeito ao passado
de neoplasias em parentes de primeiro grau,
tabagismo, tabagismo passivo, ocupação,
migração e status socioeconômico. Utilizou-
se a regressão logística não-condicional para
calcular o risco de câncer em familiares, o
efeito conjunto de câncer em familiares e uso
de tabaco, e para controlar potenciais variáveis
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RESUMO
de confusão.
RESULTADOS: O odds ratio (OR) ajustado
revelou um discreto excesso de risco para
câncer de pulmão, não estatisticamente
significante, entre os indivíduos com história
de câncer de pulmão na família (OR 1,21;
intervalo de confiança de 95% [IC 95%] 0,50
– 2,92) ou entre aqueles com história de
outros cânceres relacionados ao tabaco na
família (OR 1,36; IC 95% 0,87 –2,14). Foi
observado um efeito dose-resposta positivo
para o risco de câncer de pulmão de acordo
com o aumento do consumo de cigarros.
Detectou-se uma interação entre as variáveis
câncer na família e tabagismo.
CONCLUSÕES: Observou-se um discreto
aumento do risco de câncer de pulmão entre
indivíduos com história positiva na família de
câncer de pulmão e outros cânceres
relacionados ao tabaco. Esses resultados
sugerem que a presença de aglomerados de
câncer na família pode ser considerada como
um marcador de suscetibilidade e aumenta o
risco de câncer de pulmão entre os fumantes.
A interação detectada entre as variáveis
agregadas de câncer na família e tabagismo no
risco de câncer de pulmão é uma contribuição
no conhecimento dos mecanismos da
carcinogênese e poderá orientar futuras
pesquisas no campo da genética do câncer.
PALAVRAS-CHAVE: Câncer pulmão. Câncer na
família. Tabagismo. Estudos caso-controle.
Interação.
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